Relevance of solute carrier family 5 transporter defects to inherited and acquired human disease
- 18 Downloads
The solute carrier (SLC) group of membrane transport proteins is crucial for cells via their control of import and export of vital molecules across the cellular membrane. Defects in these transporters with narrow substrate specificities cause monogenic disorders, giving us essential clues of their precise roles in cellular functioning. The SLC5 family in particular has been linked to various human diseases, of mild and severe phenotype as well as high and low prevalence. In this review, we describe the effects on health of SLC5 dysfunction and dysregulation by summarizing findings in patients with transporter gene defects. Patients display a plethora of pathologies which include glucose/galactose malabsorption, familiar renal glycosuria, thyroid dyshormonogenesis, and distal hereditary motor neuronopathies. In addition, the therapeutic potential of intervening in transporter activities for treating common diseases such as diabetes and cancer is explored.
KeywordsSolute carriers Diabetes Cancer Sodium glucose cotransporters Glucose/galactose malabsorption
The international cooperation writing of this paper entailed was supported by the International Federation of Medical Students’ Associations (IFMSA) SCORE research exchange program.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments.
Informed consent was obtained from all individual participants in the reported studies.
- Altorjay A, Dohán O, Szilágyi A et al (2007) Expression of the Na+/I− symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus. BMC Cancer 7(5). https://doi.org/10.1186/1471-2407-7-5
- Anderson S, Koniaris S, Baozhong Xin B et al (2017) Congenital glucose–galactose malabsorption: a case report. J Pediatr Health Care 31(4). https://doi.org/10.1016/j.pedhc.2017.01.005
- Brown G K (2000) Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis 23:237–246. https://doi.org/10.1023/A:1005632012591
- Li M, Maruthur NM, Loomis SJ et al (2017) Genome-wide association study of 1,5-anhydroglucitol identifies novel genetic loci linked to glucose metabolism. Sci Rep 7(1). https://doi.org/10.1038/s41598-017-02287-x
- Pardal-Fernandez JM, Carrascosa-Romero MC, Avarez S et al (2018) A new severe mutation in the SLC5A7 gene related to congenital myasthenic syndrome type 20. Neuromuscul Disord 28:881–884. https://doi.org/10.1016/j.nmd.2018.06.020
- Ravera S, Reyna-Neyra A, Ferrandino G et al (2017) The sodium/iodide symporter (NIS): molecular physiology and preclinical and clinical applications. Annu Rev Physiol 79:261–289. https://doi.org/10.1146/annurev-physiol-022516-034125 CrossRefGoogle Scholar
- Roll P, Massacrier A, Pereira S et al (2002) New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (Infantile Convulsions and Choreoathetosis) and BFIC (Benign Familial Infantile Convulsions) families. Gene 285:141–148. https://doi.org/10.1016/S0378-1119(02)00416-X CrossRefGoogle Scholar
- Sakurai Y (2018) Autoimmune aspects of Kawasaki disease. J Investig Allergol Clin Immunol 29(4). https://doi.org/10.18176/jiaci.0300
- Wapnir IL, Van de Rijn M, Nowels K et al (2003) Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 88:1880–1888. https://doi.org/10.1210/jc.2002-021544 CrossRefGoogle Scholar
- Weber MA, Mansfield TA, Cain VA et al (2016) Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4:211–220. https://doi.org/10.1016/S2213-8587(15)00417-9 CrossRefGoogle Scholar